Global Immunoglobulin Market 2022-2028
MARKET OUTLOOK
A study by Triton Market Research suggests that the global immunoglobulin market would exhibit an uptrend trend at a CAGR of 6.77% over the forecast period of 2022-2028.
The market’s growth is supported by driving forces like the increase in the global geriatric population, increasing incidence of age-related diseases, the prevalence of autoimmune disorders, increase in research & development activities and prevalence of immunodeficiency diseases. In contrast, the high price associated with immunoglobulin therapy and the high risk of side effects due to its use are the factors that can challenge the market’s growth.
On the other hand, the increasing adoption of intravenous immunoglobulin (IVIG) treatments and the rising number of clinical trials being conducted indicate an overall positive outlook for the immunoglobulin market.
REGIONAL OUTLOOK
The immunoglobulin market covers North America, the Asia-Pacific, Europe, Latin America, the Middle East, and Africa.
North America is the global leader in the immunoglobulin market and is expected to continue its dominance until the end of the forecast period. The region is home to top companies like Pfizer Inc, CSL Behring, ADMA Biologics, and others, which supports the market’s growth.
In addition, due to the increased incidence of various diseases in the United States and Canada, the immunoglobulin market presents an opportunity for increased use of immunoglobulin. Further, it is anticipated that an increase in product approvals by the US Food and Drug Administration will increase the demand for and adoption of immunoglobulin products in the region.
COMPETITIVE OUTLOOK
The key players listed in the global immunoglobulin market include Pfizer Inc, Bio Products Laboratory, Grifols SA, Octapharma AG, China Biologic Products Inc, ADMA Biologics, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, CSL Behring, Kedrion Biopharma, Kamada Ltd, LFB Group, Sanquin Plasma Products BV, Shanghai RAAS Blood Products Co Ltd, Takeda Pharmaceutical Company Limited, and Biotest AG.
Biotest AG is a globally renowned company that supplies plasma protein products and biotherapeutic medications. Its products are primarily utilized in hematology, clinical immunology, and acute care medicine. The company’s value chain ranges from pre-clinical & clinical development to marketing and distribution. Biotest AG produces albumins, clotting factors, and immunoglobulins obtained from human blood plasma. The business was established in 1946 and currently markets its product in more than 90 nations around the globe. Biotest AG sells its goods directly through its own subsidiaries or with regional distributors and marketing partners.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook